1.	Phase III Randomized Evaluation Of Convection Enhanced Delivery Of IL13-PE38QQR (Interleukin-13 PE38QQR Immunotoxin) Compared To Gliadel® Wafer (Polifeprosan 20 With Carmustine Implant) In Glioblastoma Multiforme Patients At First Recurrence Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: NEOPHARM-IL13PEI-301, UCLA-040305101, NEOPHARM-IL13PEI-301-R01, PRECISE, NCT00076986
2.	Phase I/II Study of Interstitial Interleukin-13 PE38QQR Immunotoxin in Patients With Malignant Glioma Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: NABTT-9903, JHOC-NABTT-9903, NEOPHARM-TS-G1-TI4, NEOPHARM-IL13PEI-001-R03, NCT00006268
3.	Phase I Study of Continuous Intracerebral Infusion of Interleukin-13 PE38QQR Immunotoxin Before and After Second Resection in Patients With Recurrent Resectable Supratentorial Malignant Glioma Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: MSKCC-01141, NEOPHARM-IL13PEI-002-R01, NCI-G02-2066, NCT00036972
4.	Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recurrent Malignant Glioma Phase: Phase I Type: Diagnostic, Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: IL13PEI-105, NCT00064779